Related Experiment Videos
[Ovarian carcinoma cell inhibits T cell JAK-STAT signal transduction pathway, an experimental study]
Hui Wang1, Xing Xie, Wei-guo Lü
1Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Objective:
To investigate the effect of ovarian carcinoma cell on T cell JAK-STAT signal transduction pathway and its role in the ovarian carcinoma induced immunosupression.
Methods:
Human ovarian carcinoma cells of OVCAR3. CAOV3, and SKOV3 lines were cultured. CD8(+) T cells were isolated from the peripheral venous blood of healthy persons. Then the supernatants of these ovarian carcinoma cell lines and RPMI-1640 were added into the culture of CD8(+) T cells (groups I, II, III, and control). Thiazolyl blue (MTT) method was used to detect the growth of CD8(+) T cell. The cell cycle was examined by flow cytometry. The secretion of the Tc1 type cytokine interferon (IFN)-gamma mRNA and the secretion of the Tc2 type cytokine interleukin (IL)-10 mRNA were detected by RT-PCR. The expression of signaling molecules JAK and JAK3 and the phosphorylated activation of STAT3 and STAT5 in the CD8(+) T cell were analyzed by Western blotting.
Results:
The absorbance at the wavelength 570 nm of CD8(+) T cell culture was 0.23 +/- 0.03, 0.28 +/- 0.06, and 0.29 +/- 0.05 in the group I, II, and III, all significantly lower than that in the group IV (0.79 +/- 0.07, all P < 0.01). The percentages of CD8(+) T cells at the stage S and stage G(2)/M were lower, and those in stage G(1)/G(0) were higher in groups I, II, and III than in group IV (all P < 0.01). The IFN-gamma expression was significantly lower in groups I, II, and III in comparison with that in group IV. However, the expression of IL-10 was significantly higher in groups I, II, and III in comparison with that in group IV. The expression of JAK3 protein, but not JAK1 protein, was significantly lower in groups I, II, and III in comparison with that in group IV. The phosphorylated activation of STAT5 was suppressed significantly in groups I, II, and III, whereas the phosphorylated activation of STAT3 was suppressed only in group I.
Conclusion:
Ovarian carcinoma may suppress T cell proliferation through inhibition of the JAK-STAT signal transduction pathway, which may be a mechanism of ovarian carcinoma induced immunosuppression.
Insights
Ovarian cancer cells suppress T cell growth by inhibiting the JAK-STAT pathway, leading to immune suppression. This study reveals a key mechanism in how ovarian carcinoma affects the immune system.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Ovarian carcinoma is a significant cause of cancer-related deaths.
- Tumor-induced immunosuppression is a major challenge in cancer treatment.
- The JAK-STAT signaling pathway plays a crucial role in immune cell function.
Purpose of the Study:
- To investigate the impact of ovarian carcinoma cells on the T cell JAK-STAT signaling pathway.
- To elucidate the role of this pathway in ovarian carcinoma-induced immunosuppression.
Main Methods:
- Cultured human ovarian carcinoma cell lines (OVCAR3, CAOV3, SKOV3).
- Isolated CD8(+) T cells from healthy donors and exposed them to cancer cell supernatants.
- Assessed T cell proliferation (MTT assay), cell cycle (flow cytometry), cytokine expression (RT-PCR for IFN-gamma and IL-10), and JAK-STAT pathway activation (Western blotting for JAK1, JAK3, p-STAT3, p-STAT5).
Main Results:
- Ovarian carcinoma cell supernatants significantly inhibited CD8(+) T cell proliferation and altered cell cycle distribution.
- Exposure to cancer cells reduced IFN-gamma and increased IL-10 expression, indicating immune deviation.
- The JAK-STAT pathway was affected, with decreased JAK3 expression and suppressed STAT5 phosphorylation, and STAT3 phosphorylation in one cell line.
Conclusions:
- Ovarian carcinoma cells can suppress T cell proliferation.
- Inhibition of the JAK-STAT signaling pathway is a potential mechanism for ovarian carcinoma-induced immunosuppression.
- Targeting the JAK-STAT pathway may offer therapeutic strategies for ovarian cancer.